Primera experiencia de tratamiento con everolimus en un paciente con esclerosis tuberosa y astrocitoma subependimario de células gigantes en Uruguay

Costales, Diego; Medici, Conrado; Cerisola, Alfredo; Costa, Gonzalo; Turcati, Emilio; Dufort, Gustavo; Gonzalez, Gabriel.
Arch. med. interna (Montevideo) ; 37(3): 150-153, nov. 2015. ilus
Artículo en Español | LILACS | ID: lil-770763

Documentos relacionados

  1. Leucyl-tRNA synthetase 1 is required for proliferation of TSC-null cells.
  2. Identification of TSC1 or TSC2 mutation limited to the tumor in three cases of solitary subependymal giant cell astrocytoma using next-generation sequencing technology.
  3. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.
  4. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile.
  5. Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases.
  6. Tuberous sclerosis: a review of the past, present, and future
  7. [Analysis of genotypes, EEG and phenotypes of tuberous sclerosis complex patients].
  8. The Characterization of a Subependymal Giant Astrocytoma-Like Cell Line from Murine Astrocyte with mTORC1 Hyperactivation.
  9. [Analysis of a patient with tuberous sclerosis complex due to mosaicism TSC2 mutation].
  10. A novel de novo TSC2 nonsense mutation detected in a pediatric patient with tuberous sclerosis complex.